Wall Street analysts predict that Opko Health Inc. (NASDAQ:OPK) will post ($0.08) earnings per share for the current quarter, according to Zacks. Three analysts have provided estimates for Opko Health’s earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.10). Opko Health reported earnings per share of ($0.12) during the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The company is scheduled to report its next earnings report on Thursday, March 7th.
On average, analysts expect that Opko Health will report full year earnings of ($0.21) per share for the current year, with EPS estimates ranging from ($0.24) to ($0.17). For the next fiscal year, analysts expect that the business will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.34) to ($0.09). Zacks’ earnings per share averages are a mean average based on a survey of research firms that cover Opko Health.
Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Opko Health had a negative return on equity of 8.68% and a negative net margin of 30.24%. The firm had revenue of $250.00 million during the quarter, compared to the consensus estimate of $264.04 million. During the same quarter in the prior year, the firm posted ($0.08) EPS. The business’s revenue was up 1.6% on a year-over-year basis.
Shares of Opko Health stock traded down $0.02 on Wednesday, reaching $3.72. 1,882,472 shares of the company were exchanged, compared to its average volume of 4,021,159. Opko Health has a one year low of $2.66 and a one year high of $6.40. The stock has a market cap of $2.09 billion, a P/E ratio of -12.83 and a beta of 1.90. The company has a quick ratio of 0.78, a current ratio of 0.91 and a debt-to-equity ratio of 0.03.
In other news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the stock in a transaction on Friday, September 7th. The shares were purchased at an average price of $5.57 per share, for a total transaction of $55,700.00. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 42.74% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of Opko Health by 38.7% during the 2nd quarter. BlackRock Inc. now owns 29,531,554 shares of the biotechnology company’s stock worth $138,798,000 after purchasing an additional 8,237,434 shares in the last quarter. First Manhattan Co. grew its holdings in shares of Opko Health by 4,664.8% during the 3rd quarter. First Manhattan Co. now owns 4,290,713 shares of the biotechnology company’s stock worth $14,845,000 after purchasing an additional 4,200,663 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Opko Health by 129.9% during the 2nd quarter. Northern Trust Corp now owns 4,025,496 shares of the biotechnology company’s stock worth $18,920,000 after purchasing an additional 2,274,820 shares in the last quarter. Panagora Asset Management Inc. grew its holdings in shares of Opko Health by 199,980.6% during the 3rd quarter. Panagora Asset Management Inc. now owns 1,482,597 shares of the biotechnology company’s stock worth $5,130,000 after purchasing an additional 1,481,856 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Opko Health by 25.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,440,784 shares of the biotechnology company’s stock worth $15,363,000 after purchasing an additional 897,406 shares in the last quarter. Hedge funds and other institutional investors own 26.20% of the company’s stock.
About Opko Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Further Reading: Benefits of owning preferred stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.